20 Dec, EOD - Indian

SENSEX 78041.59 (-1.49)

Nifty 50 23587.5 (-1.52)

Nifty Bank 50759.2 (-1.58)

Nifty IT 43771.05 (-2.63)

Nifty Midcap 100 56906.75 (-2.82)

Nifty Next 50 68702.65 (-2.72)

Nifty Pharma 22501.85 (-0.86)

Nifty Smallcap 100 18714.3 (-2.19)

20 Dec, EOD - Global

NIKKEI 225 38701.9 (-0.29)

HANG SENG 19720.7 (-0.16)

S&P 6008.5 (1.05)

Login/Signup
LOGIN HERE
Cancel

Piramal Pharma Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 543635 | NSE Symbol : PPLPHARMA | ISIN : INE0DK501011 | Industry : Pharmaceuticals |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
14-Oct-2024 23-Oct-2024 Quarterly Results Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2024 inter alia to consider and approve Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September 2024 Please refer attachment (As per BSE Announcement Dated on 23/10/2024)
30-Sep-2024 30-Sep-2024 Expansion Intimation of Press Release announcing capacity expansion plan approved at the meeting of the Administrative Committee of the Board, today, on 30th Sept, 2024
15-Jul-2024 26-Jul-2024 Quarterly Results Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2024 inter alia to consider and approve Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June 2024 As per attachment. (As Per BSE Announcement dated on 26.07.2024)
30-Apr-2024 10-May-2024 Final Dividend Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2024 inter alia to consider and approve the Audited Financial Results (Standalone and Consolidated) for the financial year ended 31st March 2024 and to consider recommending payment of dividend to the shareholders. Please refer attachment. (As per BSE Announcement Dated on 10/05/2024)
17-Jan-2024 30-Jan-2024 Quarterly Results Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2024 inter alia to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 31st December 2023. Outcome of Board Meeting dated 30th January 2024 Unaudited Financial results (standalone & consolidated) for the quarter and nine months ended 31st December 2023 (As per BSE Announcement Dated on 30/01/2024)
18-Oct-2023 27-Oct-2023 Quarterly Results Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2023 inter alia to consider and approve A meeting of the Board of Directors of the Company will be held on Friday 27th October 2023 inter alia to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30th September 2023. Outcome of the Meeting of the Board of Directors of Piramal Pharma Limited (the 'Company') held on 27th October, 2023 Board Meeting Outcome - Results (As Per BSE Announcement dated on 27.10.2023)
28-Jul-2023 03-Aug-2023 Quarterly Results Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2023 inter alia to consider and approve The Board of Directors of the Company will be held on Thursday 3rd August 2023 inter alia to consider the Unaudited Financial Results (Standalone and Consolidated) of the Company for quarter ended 30th June 2023. Outcome of the Meeting of the Board of Directors of Piramal Pharma Limited held on 3rd August, 2023 (As Per BSE Announcement Dated on 03.08.2023)
18-May-2023 24-May-2023 Accounts Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2023 inter alia to consider and approve Audited Financial Results (Standalone and Consolidated) for the financial year ended 31st March 2023 Outcome of Board Meeting - Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended 31st March, 2023 (As Per BSE Announcement Dated on 23.05.2023)
25-Mar-2023 24-Mar-2023 Right Issue Intimation pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations')
01-Feb-2023 08-Feb-2023 Quarterly Results Quarterly Results Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2023 ,inter alia, to consider and approve Pursuant to Regulations 29 and 50 of the Listing Regulations, we write to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday, 08th February, 2023, inter alia to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended 31st December, 2022. Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2023 ,inter alia, to consider and approve Update on board meeting of the Company ('Board') to consider, inter alia, the proposal of fund raising by way of equity shares or other securities through rights issue as may be permitted under applicable law, subject to such regulatory/statutory approvals as may be required.meeting (As per BSE Announcement Dated on 05/02/2023) Outcome of the meeting of the board of directors of Piramal Pharma Limited (the'Company') held on 8th February, 2023 and intimation pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations') (As Per BSE Announcement dated on 08.02.2023)
01-Nov-2022 08-Nov-2022 Quarterly Results Quarterly Results Piramal Pharma Limited has informed the Exchange about Board Meeting held on 08-Nov-2022 to consider financial statements for the period ended September 2022 In continuation to our financial results for the quarter and half year ended 30th September, 2022 filed with the stock exchanges after the Board Meeting held yesterday i.e. 08th November, 2022, please find attached independent auditor's reports on these financial results with Unique Document Identification Number. (As Per NSE Announcement Dated on 09.11.2022)
1